In line with the FDA approval, fam-trastuzumab deruxtecan-nxki can be deemed as a second-line or subsequent option for treating HER2 overexpression-positive adenocarcinoma patients who have not responded to prior trastuzumab-based therapy. The gene discussed is ERBB2; the disease is adenocarcinoma.